Minakshi Saikia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Minakshi Saikia has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Kumar Singh
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, USA
1 shared publication - Nathan Cheung
Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA
1 shared publication - Vaishali Kapoor
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, USA
1 shared publication
Latest Publications
- Open Access
- 14 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8739
Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting
Molecules involved in drug resistance can be targeted for better therapeutic efficacies. Research on midkine (MDK) has escalated in the last few decades, which affirms a positive correlation between disease progression and MDK expression in most cancers and indicates its association with multi-drug resistance in cancer. MDK, a secretory cytokine found in blood, can be exploited as a potent biomarker for the non-invasive detection of drug resistance expressed in various cancers and, thereby, can be targeted. We summarize the current information on the involvement of MDK in drug resistance, and transcriptional regulators of its expression and highlight its potential as a cancer therapeutic target.
- 14 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (10) , 8739
Open AccessRole of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting
Molecules involved in drug resistance can be targeted for better therapeutic efficacies. Research on midkine (MDK) has escalated in the last few decades, which affirms a positive correlation between disease progression and MDK expression in most cancers and indicates its association with multi-drug resistance in cancer. MDK, a secretory cytokine found in blood, can be exploited as a potent biomarker for the non-invasive detection of drug resistance expressed in various cancers and, thereby, can be targeted. We summarize the current information on the involvement of MDK in drug resistance, and transcriptional regulators of its expression and highlight its potential as a cancer therapeutic target.